Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 15/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28348397 | 0.88 | FPR2 (0.76) | FPR2RAB9AFPR1MEN1LMNA | |
| SCHEMBL16738197 | 0.88 | FPR2 (0.76) | FPR2RAB9AFPR1MEN1LMNA | |
| SCHEMBL14890089 | 0.87 | FPR2 (0.74) | FPR2 | |
| SCHEMBL20983170 | 0.87 | FPR2 (0.74) | FPR2 | |
| SCHEMBL19201539 | 0.87 | FPR2 (0.74) | FPR2 | |
| SCHEMBL16738207 | 0.86 | FPR2 (0.73) | FPR2RAB9AMEN1LMNAPOLB | |
| SCHEMBL28348394 | 0.85 | FPR2 (0.81) | FPR2RAB9AFPR1 | |
| SCHEMBL16738251 | 0.85 | FPR2 (0.81) | FPR2RAB9AFPR1 | |
| SCHEMBL16588770 | 0.85 | FPR2 (0.71) | FPR2RAB9AFPR1MEN1LMNA | |
| SCHEMBL28351954 | 0.85 | FPR2 (0.71) | FPR2RAB9AFPR1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964213-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2020-11-04 | — | — | EP | claimed |
| EP-3078656-B1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-07-01 | — | — | EP | claimed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| CN-106518742-B | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor-like-1 (FPRL-1) receptor modulators | 阿勒根公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-2770989-B1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2018-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885GAA 3482/4885RAB9A 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.